Companies such as Henlius, OriCell, CStone, Gracell and Junshi presented clinical data from their PD-(L)1, cell therapy and other candidates. Henlius impresses with ES-SCLC data, Junshi boasts BTLA-targeted drug and OriCell flaunts GPRC5D-directed CAR-T
Shanghai seems to be where pharma giants are concentrating their efforts to find the next top biotech star. Johnson & Johnson, Boehringer Ingelheim, Roche, Eli Lilly, Merck and AstraZeneca have all launched initiatives to incubate or accelerate Chinese biotech startups.
Tavotek Biotherapeutics wants to take the lead in multispecific biologic therapeutics to tackle hard-to-treat tumors through its homing concept in early drug discovery and three R&D platforms to drive discovery and development.
At least 11 Chinese drugmakers are known to be developing a COVID-19 oral drug, but experts believe that regulators will need to look at phase III trials differently to approve a long-awaited homegrown COVID-19 pill